JP2006522115A - 代謝症候群の処置または予防のためａｔｉｉアンタゴニストの使用 - Google Patents

代謝症候群の処置または予防のためａｔｉｉアンタゴニストの使用 Download PDF

Info

Publication number
JP2006522115A
JP2006522115A JP2006507997A JP2006507997A JP2006522115A JP 2006522115 A JP2006522115 A JP 2006522115A JP 2006507997 A JP2006507997 A JP 2006507997A JP 2006507997 A JP2006507997 A JP 2006507997A JP 2006522115 A JP2006522115 A JP 2006522115A
Authority
JP
Japan
Prior art keywords
angiotensin
receptor antagonist
type
daily dose
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006507997A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006522115A5 (https=
Inventor
リュンググレン，アンダース
スヴェンソン，アンダース
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2006522115A publication Critical patent/JP2006522115A/ja
Publication of JP2006522115A5 publication Critical patent/JP2006522115A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2006507997A 2003-04-03 2004-03-31 代謝症候群の処置または予防のためａｔｉｉアンタゴニストの使用 Pending JP2006522115A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0300988A SE0300988D0 (sv) 2003-04-03 2003-04-03 New use
PCT/SE2004/000505 WO2004087136A1 (en) 2003-04-03 2004-03-31 Use of atii antagonist for the treatment or prevention of metabolic syndrome

Publications (2)

Publication Number Publication Date
JP2006522115A true JP2006522115A (ja) 2006-09-28
JP2006522115A5 JP2006522115A5 (https=) 2007-04-05

Family

ID=20290927

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006507997A Pending JP2006522115A (ja) 2003-04-03 2004-03-31 代謝症候群の処置または予防のためａｔｉｉアンタゴニストの使用

Country Status (15)

Country Link
US (1) US20060194856A1 (https=)
EP (1) EP1613309A1 (https=)
JP (1) JP2006522115A (https=)
KR (1) KR20050114671A (https=)
CN (1) CN1771033A (https=)
AU (1) AU2004226517B2 (https=)
BR (1) BRPI0408979A (https=)
CA (1) CA2520960A1 (https=)
IL (1) IL170706A0 (https=)
MX (1) MXPA05010660A (https=)
NO (1) NO20054370L (https=)
NZ (1) NZ542640A (https=)
SE (1) SE0300988D0 (https=)
WO (1) WO2004087136A1 (https=)
ZA (1) ZA200507945B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008067378A2 (en) * 2006-11-28 2008-06-05 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted phenyltetrazoles
JP2015509969A (ja) * 2012-03-16 2015-04-02 グルソックス・バイオテック・アーベー Ｎｏｘ４阻害活性を示すチオフェン−ベースの化合物および療法におけるその使用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04364171A (ja) * 1990-04-27 1992-12-16 Takeda Chem Ind Ltd ベンズイミダゾール誘導体
WO2001076574A2 (en) * 2000-04-12 2001-10-18 Novartis Ag Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists
WO2002040007A1 (en) * 2000-11-17 2002-05-23 Novartis Ag Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
WO2002096358A2 (en) * 2001-05-30 2002-12-05 Bristol-Myers Squibb Company Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266583A (en) * 1992-09-01 1993-11-30 Merck & Co., Inc. Angitotensin II antagonist
GB9406573D0 (en) * 1994-03-31 1994-05-25 Merck Sharp & Dohme Medicaments
DE4439947A1 (de) * 1994-11-09 1996-05-15 Boehringer Mannheim Gmbh 2,2-Dichloralkancarbonsäuren, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
NZ509260A (en) * 1998-07-10 2003-09-26 Novartis Ag Pharmaceutical composition containing valsartan and a calcium channel blocker
CA2420055C (en) * 2000-08-25 2010-06-01 Takeda Chemical Industries, Ltd. Fibrinogen-lowering agent
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
EP1579872B8 (en) * 2002-12-27 2012-11-07 Takeda Pharmaceutical Company Limited Body weight gain inhibitor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04364171A (ja) * 1990-04-27 1992-12-16 Takeda Chem Ind Ltd ベンズイミダゾール誘導体
WO2001076574A2 (en) * 2000-04-12 2001-10-18 Novartis Ag Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists
WO2002040007A1 (en) * 2000-11-17 2002-05-23 Novartis Ag Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
WO2002096358A2 (en) * 2001-05-30 2002-12-05 Bristol-Myers Squibb Company Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method

Also Published As

Publication number Publication date
US20060194856A1 (en) 2006-08-31
MXPA05010660A (es) 2005-12-12
IL170706A0 (en) 2009-02-11
NZ542640A (en) 2008-06-30
AU2004226517A1 (en) 2004-10-14
NO20054370D0 (no) 2005-09-21
AU2004226517B2 (en) 2008-01-24
ZA200507945B (en) 2007-04-25
WO2004087136A1 (en) 2004-10-14
CN1771033A (zh) 2006-05-10
KR20050114671A (ko) 2005-12-06
BRPI0408979A (pt) 2006-04-04
CA2520960A1 (en) 2004-10-14
EP1613309A1 (en) 2006-01-11
NO20054370L (no) 2005-10-31
SE0300988D0 (sv) 2003-04-03

Similar Documents

Publication Publication Date Title
JP4938905B2 (ja) 選択的ｓ１ｐ１レセプターアゴニストの投与法
EP2545920A1 (en) Therapy for complications of diabetes
Stein et al. Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia
JP2018508551A (ja) 心血管疾患を処置するか又は心血管疾患のリスクを低減させるためのｅｔｃ１００２及び１種以上のスタチンを含む固定用量配合剤
WO2019222564A1 (en) Methods and compositions for treatment of alzheimer's disease
JP2017531676A (ja) Ｐｇｉ２受容体に関連した状態の治療法
EA028060B1 (ru) Комбинированная терапия бокового амиотрофического склероза
EP3302460A1 (en) Sacubitril and valsartan for treating metabolic disease
JP2006522115A (ja) 代謝症候群の処置または予防のためａｔｉｉアンタゴニストの使用
US20200179369A1 (en) Treatment of diabetic nephropathy
US20080051438A1 (en) Preventive/Therapeutic Compositions Useful for Treating Cardiovascular Diseases
JP6227535B2 (ja) 脂質異常症の予防又は治療薬
CN104053441B (zh) 用于预防或治疗高脂血症的药物组合物
TW201922243A (zh) 藥物組成物以及包括其的複合製劑
AU2002319535B2 (en) The treatment of lipodystrophy
Hoffbrand et al. Comparison of nisoldipine and nifedipine as additional treatment in hypertension inadequately controlled by atenolol
KR101579656B1 (ko) 프라바스타틴과 발사르탄을 포함하는 약학 조성물
JP2009256209A (ja) 降圧療法
Weir et al. Use of angiotensin II receptor blockers alone and in combination with other drugs: a large clinical experience trial

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100914

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110419